精測電子(300567.SZ):沈亞非已完成減持65萬股並承諾12個月內不減持
格隆匯9月6日丨精測電子(300567.SZ)公佈,近日,公司收到沈亞非出具的《關於減持精測電子股份的吿知函》。截止公吿披露日,沈亞非本次減持計劃已實施完成。沈亞非於2021年9月6日通過大宗交易減持公司股份65萬股,減持比例為公司股份總數的0.23%。
截止公吿披露日,沈亞非持有公司股份210.9478萬股,佔公司總股本的0.76%。基於對公司未來發展信心以及對公司內在價值認可,同時為增強廣大投資者信心,切實維護投資者權益和資本市場的穩定,沈亞非先生自願承諾:自本承諾函出具之日起十二個月內,本人不會通過集中競價交易、大宗交易或協議轉讓等方式減持所持公司的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.